Tapinarof - Celestial Pharmaceuticals/Stiefel Laboratories/Welichem Biotech

Drug Profile

Tapinarof - Celestial Pharmaceuticals/Stiefel Laboratories/Welichem Biotech

Alternative Names: Benvitimod; DHPS; GSK-2894512; WBI-1001

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Welichem Biotech
  • Developer Beijing Wenfeng Tianji Pharmaceuticals; Celestial Pharmaceuticals; Stiefel Laboratories; Welichem Biotech
  • Class Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Aryl hydrocarbon receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriasis
  • Phase II Atopic dermatitis; Plaque psoriasis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 12 Jul 2018 Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
  • 06 Dec 2017 GlaxoSmithKline withdraws a phase III trial prior to enrolment due to a business decision for Plaque psoriasis (Topical, Cream) (NCT03202004)
  • 29 Nov 2017 GlaxoSmithKline withdraws a phase I trial for Psoriasis (In volunteers) prior to enrolment, before November 2017 (NCT03201978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top